Ionis Pharmaceuticals (IONS) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $9.01B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Brett Monia |
| IPO Date | 1991-05-17 | CAGR | 19.23% |
| Employees | 1,480 | Website | www.ionispharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $14.66B | P/E | -31.52 | Forward P/E | -48.74 | PEG | — |
| P/S | 164.35 | P/B | 326.68 | P/CF | -289.5 | P/FCF | -257.23 |
| Sales | $873.76M | Sales 1Y | -7.45% | Sales 3Y | 38.56% | Sales 5Y | 27.05% |
| EPS | $-1.72 | EPS 1Y | 86.02% | EPS 3Y | 60.19% | EPS 5Y | -10.36% |
| Sales QoQ | 8.88% | EPS QoQ | 23.21% | Sales QoQ Avg | -1.42% | EPS QoQ Avg | -44.62% |
| Gross Margin | 98.16% | Operating Margin | -68.09% | Profit Margin | -64.64% | ROCE | -22.21% |
| ROA | -19% | ROE | -111% | Altman Z Score | 1.42 | Piotroski Score | 2 |
| Current Ratio | 7.89 | Quick Ratio | 7.73 | Cash Ratio | 1.11 | Op. CF Ratio | 1.79 |
| Debt/Equity | 3.67 | Debt/Assets | 0.54 | Lt Debt/Equity | 4.27 | Lt Debt/Cap. | 0.79 |
| Intrst Cov. | -9.48 | Inventory Turnover | 0.32 | Asset Turnover | 0.29 | Receivables Turnover | 14.85 |
| Enterprise Value | $14.66B | P/E Ratio | -31.52 |
| Forward P/E | -48.74 | PEG Ratio | — |
| P/S Ratio | 164.35 | P/B Ratio | 326.68 |
| P/CF Ratio | -289.5 | P/FCF Ratio | -257.23 |
| EPS | $-1.72 | EPS Growth 1Y | 86.02% |
| EPS Growth 3Y | 60.19% | EPS Growth 5Y | -10.36% |
| Revenue Growth 1Y | -7.45% | Gross Margin | 0.98% |
| Operating Margin | -0.68% | Profit Margin | -0.65% |
| ROE | -1.11% | ROA | -0.19% |
| ROCE | -0.22% | Current Ratio | 7.89 |
| Quick Ratio | 7.73 | Cash Ratio | 1.11 |
| Debt/Equity | 3.67 | Interest Coverage | -9.48 |
| Altman Z Score | 1.42 | Piotroski Score | 2 |
Ionis Pharmaceuticals (IONS) valuation & financials
Ionis Pharmaceuticals (IONS) has a market capitalization of $9.01B and trades at a price-to-earnings ratio of -31.5. It operates in the Healthcare sector (Biotechnology).
Ionis Pharmaceuticals's revenue grew -7.4% over the last year.
Ionis Pharmaceuticals's next earnings report is scheduled for November 4, 2026 before market open; analysts estimate EPS of $-1.21. Check the earnings calendar to see all companies reporting this week.
Ionis Pharmaceuticals (IONS) — frequently asked questions
When does Ionis Pharmaceuticals (IONS) report earnings next?
Ionis Pharmaceuticals is expected to report earnings on November 4, 2026 before market open. Analysts estimate EPS of $-1.21.
What is Ionis Pharmaceuticals's market cap?
Ionis Pharmaceuticals (IONS) has a market capitalization of $9.01B.
What is IONS's P/E ratio?
Ionis Pharmaceuticals trades at a price-to-earnings ratio of -31.5, with trailing twelve-month EPS of $-1.72.
How fast is Ionis Pharmaceuticals growing?
Ionis Pharmaceuticals's revenue grew -7.4% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)